Berk J L, Hagen J F, Koo R
Ann Surg. 1976 Apr;183(4):369-76. doi: 10.1097/00000658-197604000-00007.
Recent studies demonstrated that epinephrine causes significant pulmonary A-V shunting. This study reports the effect of alpha and beta adrenergic blockade on this shunting. Sixty-three anesthetized mongrel dogs were ventilated with a mechanical respirator. Measurements of (1) the pulmonary shunt, (2) cardiac output, (3) mean pulmonary artery, pulmonary capillary wedge and systemic pressures, and (4) pulmonary and systemic vascular resistances were obtained at 5, 15 and 30 minute intervals during the first hour and hourly for 5 hours. Fifteen dogs received no treatment. All others received epinephrine hydrochloride, 2 mug/kg/min for 5 hours. Ten received epinephrine only. Ten were pretreated with propranolol hydrochloride, 250 mug/kg, 12 with phenoxybenzamine, 1 mg/kg, and 16 with phenoxybenzamine and propranolol. Propranolol significantly decreased the epinephrine induced pulmonary shunt at all times and was the most effective drug. Phenoxybenzamine decreased the early shunting, but less than propranolol, and did not decrease the late shunting. Blockade with propranolol and phenoxybenzamine was less effective than propranolol alone. Based on the observed hemodynamic changes it was suggested that beta blockade is effective in reducing epinephrine induced pulmonary insufficiency by favorably altering the flow and distribution of pulmonary blood flow which in turn decreases epinephrine induced ventilation-perfusion inequalities and capillary hypertension both of which result in shunting. Conversely phenoxybenzamine has an unfavorable effect on the pulmonary flow. These studies support previous work in animals and man which showed that beta adrenergic stimulation is important in the pathogenesis of pulmonary insufficiency. Because the amounts of epinephrine used produce blood levels observed in critical illness, these studies add support to a relationship between the increased catecholamine stimulation of critical illness and the associated and often unexplained pulmonary insufficiency.
近期研究表明,肾上腺素可导致显著的肺动静脉分流。本研究报告了α和β肾上腺素能阻滞对此种分流的影响。63只麻醉的杂种犬用机械呼吸机通气。在最初1小时内每隔5、15和30分钟,以及在随后5小时内每小时测量一次:(1)肺分流;(2)心输出量;(3)平均肺动脉压、肺毛细血管楔压和体循环压力;(4)肺血管阻力和体循环血管阻力。15只犬未接受治疗。所有其他犬接受盐酸肾上腺素,以2μg/kg/min的速度输注5小时。10只犬仅接受肾上腺素。10只犬预先用250μg/kg盐酸普萘洛尔处理,12只犬用1mg/kg苯氧苄胺处理,16只犬用苯氧苄胺和普萘洛尔处理。普萘洛尔在所有时间均显著降低肾上腺素诱导的肺分流,是最有效的药物。苯氧苄胺可降低早期分流,但效果不如普萘洛尔,且不能降低后期分流。普萘洛尔和苯氧苄胺联合阻滞的效果不如单独使用普萘洛尔。基于观察到的血流动力学变化,提示β阻滞通过有利地改变肺血流的流量和分布,从而有效减少肾上腺素诱导的肺功能不全,这反过来又减少了肾上腺素诱导的通气-灌注不均和毛细血管高压,二者均导致分流。相反,苯氧苄胺对肺血流有不利影响。这些研究支持了先前在动物和人类中的研究工作,这些研究表明β肾上腺素能刺激在肺功能不全的发病机制中起重要作用。由于所用肾上腺素的量产生了危重病时观察到的血药浓度,这些研究进一步支持了危重病时儿茶酚胺刺激增加与相关且常无法解释的肺功能不全之间的关系。